ArticleFrontiers in immunology2025
Circulating fibroblasts and neutrophils co-expressing CDH11
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs.Frontiers in immunology · 2026Review
- Reduced fibroblast-derived IGFBP5 is associated with pathogenic synovial fibroblast states and altered macrophage polarization in rheumatoid arthritis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanisms underlying the progression of chronic inflammatory arthritis remain largely unclear. Methods: We used single-cell mass cytometry on peripheral blood from patients with active rheumatoid arthritis (RA; n=11), psoriatic arthritis (PsA; n=12), and controls (n=9) to identify circulating cells co-expressing mesenchymal markers, including the homotypic adhesion molecule cadherin-11 (CDH11), and chemokine receptors. Proteomic profiling was performed on matched plasma using Olink. Confocal microscopy was used to investigate cell localization in synovial tissue. Results: Circulating cells co-expressing mesenchymal markers, including the adhesion molecule cadherin-11 (CDH11) and chemokine receptors, were identified. Of them, circulating fibroblasts (podoplanin Conclusions: Combining our findings with previous data showing circulating pre-inflammatory mesenchymal cells preceding rheumatoid arthritis flares, we propose that a chemokine-orchestrated process, that seems to not being affected by short-term Disease-Modifying Antirheumatic Drug (DMARD) treatment, may contribute to 'arthritis spreading' in both RA and PsA. In this chronic process synovial fibroblasts and fibrocytes with pathogenic potential may migrate into distant synovium through CDH11-mediated homotypic binding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.